Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002881 · ClinicalTrials.gov registry record · Phase 3
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002881 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00002881, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
Interventions
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG flutamide
- DRUG therapeutic hydrocortisone
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002881
The ClinicalTrials.gov registry entry for NCT00002881 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00002881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002881 about?
NCT00002881 is a clinical study titled "Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer". RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
What is the current status of trial NCT00002881?
This trial is currently completed. It is a Phase 3 study. The study started on 1996-10.
What interventions are being tested in trial NCT00002881?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin acetate (DRUG), flutamide (DRUG), therapeutic hydrocortisone (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002881?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.